Fabrazyme
Fabrazyme is an enzyme replacement therapy designed to treat Fabry disease, a rare genetic disorder caused by the deficiency of the alpha-galactosidase A enzyme. The medication works by replacing the missing enzyme, helping to break down harmful fatty substances that accumulate in the cells of patients with this condition. It is administered via intravenous infusion and is intended for long-term treatment in both adults and children.
Fabrazyme is an enzyme replacement therapy used to treat Fabry disease by replacing the deficient alpha-galactosidase A enzyme.
Key facts at a glance
- RxNorm
- 338818
- Generic
- Fabrazyme
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Fabrazyme is indicated for the treatment of Fabry disease in adults and children. It is used in patients with confirmed diagnosis of Fabry disease who have characteristic symptoms such as neuropathic pain, skin lesions, renal impairment, cardiac complications, or cerebrovascular disease.
Fabrazyme contains the active ingredient agalsidase beta, a recombinant form of the human enzyme alpha-galactosidase A. It works by breaking down and reducing the accumulation of globotriaosylceramide (GL-3/Gb3) in the cells of various tissues, including blood vessel walls, kidneys, heart, and nervous system.
Fabrazyme is administered by intravenous infusion, typically every two weeks. Common side effects may include infusion reactions such as fever, chills, and flushing. Premedication with antihistamines and/or corticosteroids may be recommended to reduce the risk of infusion reactions. Patients should be monitored for signs of anaphylaxis during infusion. This medication should be used during pregnancy only if clearly needed, and women of childbearing potential should use effective contraception during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy